These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38327048)

  • 1. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.
    Zhou Z; Li J; Ousmane D; Peng L; Yuan X; Wang J
    Mol Ther; 2024 Mar; 32(3):572-579. PubMed ID: 38327048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular understanding of super-enhancer dysregulation in cancer.
    Yoshino S; Suzuki HI
    Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super-enhancers in cancer.
    Thandapani P
    Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
    Bacabac M; Xu W
    Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Super-enhancers include classical enhancers and facilitators to fully activate gene expression.
    Blayney JW; Francis H; Rampasekova A; Camellato B; Mitchell L; Stolper R; Cornell L; Babbs C; Boeke JD; Higgs DR; Kassouf M
    Cell; 2023 Dec; 186(26):5826-5839.e18. PubMed ID: 38101409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super enhancer lncRNAs: a novel hallmark in cancer.
    Song P; Han R; Yang F
    Cell Commun Signal; 2024 Apr; 22(1):207. PubMed ID: 38566153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status.
    Vasileva AV; Gladkova MG; Ashniev GA; Osintseva ED; Orlov AV; Kravchuk EV; Boldyreva AV; Burenin AG; Nikitin PI; Orlova NN
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etiology of super-enhancer reprogramming and activation in cancer.
    Zhou RW; Parsons RE
    Epigenetics Chromatin; 2023 Jul; 16(1):29. PubMed ID: 37415185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies.
    Dębek S; Juszczyński P
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Super-enhancers in transcriptional regulation and genome organization.
    Wang X; Cairns MJ; Yan J
    Nucleic Acids Res; 2019 Dec; 47(22):11481-11496. PubMed ID: 31724731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The super-enhancer repertoire in porcine liver.
    Zhang Y; Zhang J; Wang C; Dai H; Du X; Li Q; Pan Z
    J Anim Sci; 2023 Jan; 101():. PubMed ID: 36800318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program.
    Kalna V; Yang Y; Peghaire CR; Frudd K; Hannah R; Shah AV; Osuna Almagro L; Boyle JJ; Göttgens B; Ferrer J; Randi AM; Birdsey GM
    Circ Res; 2019 Apr; 124(9):1337-1349. PubMed ID: 30892142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Super-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis.
    Suzuki HI; Young RA; Sharp PA
    Cell; 2017 Mar; 168(6):1000-1014.e15. PubMed ID: 28283057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifaceted regulation of enhancers in cancer.
    Xiao Q; Xiao Y; Li LY; Chen MK; Wu M
    Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194839. PubMed ID: 35750313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Validation and Prediction of Super-Enhancers: Advances and Challenges.
    Kravchuk EV; Ashniev GA; Gladkova MG; Orlov AV; Vasileva AV; Boldyreva AV; Burenin AG; Skirda AM; Nikitin PI; Orlova NN
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Super-Enhancers Dysregulations in Hematological Malignancies.
    Belloucif Y; Lobry C
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-sensitive super enhancers form domains of coordinately regulated enhancer RNAs.
    Hah N; Benner C; Chong LW; Yu RT; Downes M; Evans RM
    Proc Natl Acad Sci U S A; 2015 Jan; 112(3):E297-302. PubMed ID: 25564661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.
    Hnisz D; Schuijers J; Lin CY; Weintraub AS; Abraham BJ; Lee TI; Bradner JE; Young RA
    Mol Cell; 2015 Apr; 58(2):362-70. PubMed ID: 25801169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
    Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
    Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2.
    Cui S; Wu Q; Liu M; Su M; Liu S; Shao L; Han X; He H
    Cell Death Dis; 2021 Mar; 12(3):264. PubMed ID: 33712565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.